Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

Acute Lung Injury Clinical Trial

— PRESSURE  

Official title:

Primary Resuscitation Using Airway Pressure Release Ventilation Improves Recovery From Acute Lung Injury or Adult Respiratory Distress Syndrome and Reduces All Cause Mortality Compared to ARDS Net Low Tidal Volume-Cycled Ventilation.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00793013
• Other study ID #: 123456789
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 2, 2020
• Est. completion date: November 2, 2020

Study information

• Verified date: November 2020
• Source: University of Tennessee, Chattanooga
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Traditional modes of ventilation have failed to improve patient survival. Subsequent observations that elevated airway pressures observed in traditional forms of ventilation resulted in barotrauma and extension of ALI lead to the evolution of low volume cycled ventilation as a potentially better ventilatory modality for ARDS. Recent multicenter trials by the NIH-ARDS network have confirmed that low volume ventilation increases the number of ventilatory free days and improves overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.

Description:

Low volume ventilation may increase number of ventilatory free days and may improve overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2, 2020
• Est. primary completion date: November 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• All patients admitted to the Internal Medicine service at the Baroness Erlanger Hospital of the University of Tennessee College of Medicine with hypoxia (O2 saturation < 93%) and pulmonary distress, will be screened for study participation.
• Patients displaying all the following clinical criteria: acute onset of respiratory failure; hypoxia defined as a PaO2/FiO2 ratio of < 300 Torr; pulmonary capillary wedge pressure less or equal than 18 mm Hg, and/or no clinical evidence of left sided heart failure; and chest x-ray with diffuse bilateral pulmonary infiltrates.

Exclusion Criteria:

• Patients receiving conventional volume ventilation with or without PEEP for > 6 hours prior to study enrollment
• Patient's family or surrogate unwilling to give informed consent
• Patients requiring sedation or paralysis for effective ventilation
• Patients known pulmonary embolus within 72 hours of study enrollment
• Patients with close head injuries or evidence of increased intracranial pressure
• Patients with burns over 30% of total body surface area
• Pulmonary capillary wedge pressure greater than 18 mm Hg
• CVP > 15 cm H2O
• Patients with B type Naturetic peptide levels > 1000
• Patients with prior history of dilated cardiomyopathy with EF < 25%
• Patients receiving chronic outpatient peritoneal or hemodialysis
• Patients with severe liver disease (as defined by Child-Pugh class C)
• AIDS patients

Related Conditions & MeSH terms

• Acute Lung Injury
• Adult Respiratory Distress Syndrome
• Kidney Injury
• Lung Injury
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn
• Syndrome
• Wounds and Injuries

Intervention

Device:
• Volume-Cycled Assist-Control (AC) mode
Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40% Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2 Inspiratory to Expiratory ratio set at 1:1 to 1:3 If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased Mgmt of PEEP will be conducted as per the ARDSnet Protocol Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95% Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
• Airway Pressure Release Ventilation (APRV) mode
Ventilation uses Drager Model X1 Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels Time periods for the high & low pressure levels can be set independently Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min Spontaneous frequency will be targeted for 6 to 18 breaths/per min If spontaneous breathing is achieved,level of sedation will be decreased If spontaneous respirations are >20 breaths/min, sedation will be increased If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased

Locations

Country	Name	City	State
United States	James A. Tumlin, MD	Chattanooga	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
University of Tennessee, Chattanooga

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All cause mortality		28 days or prior to hospital discharge
Secondary	Number of ventilator-free days		28 days or prior to hospital discarge
Secondary	Length of ICU stay and /or Total hospital days		28 days or prior to hospital discharge
Secondary	To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the incidence of of AKI		28 days or prior to hospital discharge
Secondary	To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the NGAL, KIM-1, and IL-18 urine biomarkers for AKI		28 days or prior to hospital discharge
Secondary	To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation in maintaining hourly urine output > 0.5 mls/kg/hr		28 days or prior to hospital discharge
Secondary	Will determine urinary aquaporin-2 levels in patients randomized to APRV ventilation versus ARDS net low volume-cycle ventilation		28 days or prior to hospital discharge